A retrospective study: multiply recurrent intracranial germ cell tumors
- 1Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University
- 2Department of Neuro-oncology, Sanbo Brain Hospital, Capital Medical University
Abstract
Purpose: Intracranial germ cell tumors (GCTs) are a rare group of malignancies that are prone to recurrence and dissemination. The management of patients with multiple recurrent GCTs is particularly challenging. This study aimed to summarize the clinical characteristics of intracranial GCTs with multiple recurrences (≥3 times) and to provide a basis for improving prognosis.
Methods: We collected clinical data from patients with multiply recurrent (≥3 times) intracranial GCTs treated at Sanbo Brain Hospital between 2016 and 2023. Data included sex, age, histological diagnosis, number of recurrences, tumor location, treatment regimens, and survival outcomes. Treatment modalities at initial diagnosis and each recurrence were recorded. Progression-free survival (PFS) intervals between recurrences were compared, and overall survival (OS) was analyzed.
Results: A total of 49 patients were included: 13 with pure germinomas and 36 with non-germinomatous germ cell tumors (NGGCTs). The cohort included 39 (79.6%) males and 10 (20.4%) females, with a mean age at initial presentation of 13.29 ± 5.99 years. The number of recurrences ranged from 3 to 11. Overall survival of germinoma patients was significantly better than that of NGGCT patients (P = 0.0019). For both germinomas and NGGCTs, the PFS interval between first and second recurrences (PFS2) was significantly shorter than that from initial diagnosis to first recurrence (PFS1) (P = 0.0286 and P = 0.0428, respectively). The Friedman test demonstrated significant shortening of PFS intervals with successive recurrences in both germinomas (P<0.0001) and NGGCTs (P = 0.0092).
Conclusion: For patients with multiply recurrent GCTs, management increasingly relies on systemic chemotherapy as local modalities become less feasible. In addition, the interval between recurrences shortens with successive relapses, with the time to the second recurrence being significantly shorter than that to the first in both germinomas and NGGCTs.
Related
- Case Report: Intracranial germ cell tumors in girls presenting with peripheral precocious puberty and arginine vasopressin deficiency
- Mitochondrial priming in human germ cell tumors is dependent on MCL1 and BCL2L1
- Multiply recurrent pituitary apoplexy treated nonsurgically: illustrative case.
- From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
- XPO1 Inhibition by Selinexor Induces Nuclear p53 and p21 Accumulation, Cell-Cycle Arrest and Apoptosis in Testicular Germ Cell Tumors
BibTeX
@article{zhao2026retrospective,
title = {{A retrospective study: multiply recurrent intracranial germ cell tumors}},
author = {Chuan Zhao and Jingjing Ge and Cheng Li and Chi Zhao and Shaopei Qi and Fengjun Xue and Jingjing Zhang and Junping Zhang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1962932},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1962932/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A retrospective study: multiply recurrent intracranial germ cell tumors
AU - Chuan Zhao
AU - Jingjing Ge
AU - Cheng Li
AU - Chi Zhao
AU - Shaopei Qi
AU - Fengjun Xue
AU - Jingjing Zhang
AU - Junping Zhang
PY - 2026
DA - 2026/10/19
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1962932
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1962932/full
AB - Purpose: Intracranial germ cell tumors (GCTs) are a rare group of malignancies that are prone to recurrence and dissemination. The management of patients with multiple recurrent GCTs is particularly challenging. This study aimed to summarize the clinical characteristics of intracranial GCTs with multiple recurrences (≥3 times) and to provide a basis for improving prognosis. Methods: We collected clinical data from patients with multiply recurrent (≥3 times) intracranial GCTs treated at Sanbo Brain Hospital between 2016 and 2023. Data included sex, age, histological diagnosis, number of recurrences, tumor location, treatment regimens, and survival outcomes. Treatment modalities at initial diagnosis and each recurrence were recorded. Progression-free survival (PFS) intervals between recurrences were compared, and overall survival (OS) was analyzed. Results: A total of 49 patients were included: 13 with pure germinomas and 36 with non-germinomatous germ cell tumors (NGGCTs). The cohort included 39 (79.6%) males and 10 (20.4%) females, with a mean age at initial presentation of 13.29 ± 5.99 years. The number of recurrences ranged from 3 to 11. Overall survival of germinoma patients was significantly better than that of NGGCT patients (P = 0.0019). For both germinomas and NGGCTs, the PFS interval between first and second recurrences (PFS2) was significantly shorter than that from initial diagnosis to first recurrence (PFS1) (P = 0.0286 and P = 0.0428, respectively). The Friedman test demonstrated significant shortening of PFS intervals with successive recurrences in both germinomas (P<0.0001) and NGGCTs (P = 0.0092). Conclusion: For patients with multiply recurrent GCTs, management increasingly relies on systemic chemotherapy as local modalities become less feasible. In addition, the interval between recurrences shortens with successive relapses, with the time to the second recurrence being significantly shorter than that to the first in both germinomas and NGGCTs.
SN - 2234-943X
ER -